Home Knowledge Bank Organizations Buyer List Hospital Projects Audience Advertise Contact Us   Search For Web  Knowledge Bank News Research Insight Techno Trends Industry Reports Articles  Industry Events & Exhibition Industry Projects Case Studies White Papers Book Shelf  Publishing Press Releases e-mailer e-newsletter Webinars / Videos Advertise Print Online Subscribe     News    Amic signs an agreement with Roche Diagnostics Thursday 3 Jan, 2008   Amic AB has been granted a non-exclusive license under patent rights of Roche Diagnostics to   commercialise a point-of-care (POC) test for NT-proBNP in the European market. NT-proBNP is a cardiac   marker for a broad range of cardiovascular conditions, comprising the diagnosis and management of heart   failure, and risk stratification of patients with acute coronary syndrome. Speaking on the occasion, Lars   Gunneflo, CEO, Amic AB, said, "This agreement with Roche Diagnostics marks a major milestone in Amic's   development. The NT-proBNP test will be one of the first to be launched on our Forecast POC diagnostic   system. The market for NT-proBNP testing is growing significantly in Europe, and we see great potential in   the future for monitoring and managing the treatment of heart failure patients at the point of care."   Copyrights © 2007 Avni Media Private Limited.